Find the Perfect Plan for Your Investment Journey
Last Price
52 Week Range
$233.31 - $417.82
Next Earnings Date
Apr 30 2025
Next Earnings Date
Apr 30 2025
Last Price
Market Cap | $13.51B |
EV | $9.10B |
Shares Outstanding | 47.73M |
Beta | 0.63 |
Analyst Rating | OUTPERFORM |
Analyst Target Price | $388.02 |
P/E 2025E | 11.02x |
P/Revenue 2025E | 4.30x |
Revenue | 19.50% |
EPS | 34.80% |
Operating Cash Flow | 30.40% |
Free Cash Flow | 31.30% |
Revenue | 7.30% |
EPS | 5.50% |
Operating Cash Flow | 15.70% |
Free Cash Flow | 12.80% |
Gross Margin 2025E | 89.01% |
Net Profit Margin 2025E | 42.40% |
ROE 2025E | 19.30% |
ROCE 2024 | 19.23% |
DPS 2025E | $0.00 |
Payout Ratio 2025E | 0.00% |
Div. Yield 2025E | 0.00% |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
United Therapeutics Corporation
UTHR
Sector
Healthcare
Industry
Biotechnology
CEO
Rothblatt, Martine
Employees
1,305
Website
www.unither.comIPO Date
1999-06-17
Headquarters
1000 Spring Street, Silver Spring, Maryland, 20910, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved